It has been another busy month reporting the latest bariatric and metabolic, and obesity-related disease news. We hope we have brought you the latest and most interesting news as it happened. Here are the Top 10 most read articles on Bariatric News in September 2022.
Bariatric surgery results in improvements in pain, physical function and work productivity for at least seven years after surgery, according to the outcomes from the National Institutes of Health-funded Longitudinal Assessment of Bariatric Surgery-2 (LABS-2), a prospective, cohort study of US patients undergoing bariatric surgery.
Intraoperative indocyanine green (ICG) testing may be helpful in determining which patients are at an increased risk of leakage after a laparoscopic sleeve gastrectomy (LSG) and if adjunctive measures are needed intraoperatively, according to researchers from the University of Foggia, Foggia, Italy. However, the investigators stated that further testing is required to determine if ICG will predict leakage due to ischaemia. The findings were featured in the paper, ‘Can indocyanine green during laparoscopic sleeve gastrectomy be considered a new intraoperative modality for leak testing?’, published in BMC Surgery.
Researchers from the Western University in London, Canada, have reported that patients with a history of bariatric surgery were at increased risk of developing epilepsy, the findings suggest that epilepsy is a long-term risk associated with bariatric surgery for weight loss.
Molecular mechanisms of brain development during early life are likely a major determinant of obesity risk, according to researchers at Baylor College of Medicine and collaborating institutions. The findings were featured in the paper, 'Sex-specific epigenetic development in the mouse hypothalamic arcuate nucleus pinpoints human genomic regions associated with body mass index', Science Advances.
Adolescents suffering with severe obesity who underwent bariatric surgery before the age of 22 had significant and lasting reductions in weight and comorbidities after surgery, according to researchers from UTHealth Houston and the University of Miami. The researchers believe the study contains the longest follow-up data currently available on adolescents suffering with severe obesity after weight-loss surgery, revealing that they lost 31.3% of their weight and kept it off more than a decade later. They also had a 100% remission in diabetes, asthma, and elevated lipids. The results of the study, ‘Long-Term Outcomes after Adolescent Bariatric Surgery’, were published in the Journal of the American College of Surgeons.
The Institute for Clinical and Economic Review (ICER) in the US has published its revised Evidence Report assessing the comparative clinical effectiveness and value of subcutaneous semaglutide (Wegovy, Novo Nordisk), liraglutide (Saxenda, Novo Nordisk), phentermine/topiramate (Qsymia, Vivus Pharmaceuticals), and bupropion/naltrexone (Contrave, Currax Pharma) for the treatment of obesity.
Researchers led by Dr Ali Tavakkoli, Chief of the division of General and GI Surgery and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, have demonstrated that a LuCI (Luminal Coating of the Intestine), an orally administered intestine barrier coating, can ameliorate weight gain and improve insulin sensitivity in a long-term DIO rat model. The findings were presented in the paper, ‘‘Luminal Coating of Intestines: a potential novel anti-obesity therapy for obesity-associated type 2 diabetes,’ at the 25th World Congress of the International Federation Surgery of Obesity and Metabolic Disorders in Miami, FL.
A team led by Van Andel Institute scientists has identified two distinct types of obesity with physiological and molecular differences that may have lifelong consequences for health, disease and response to medication. The findings, ‘Independent phenotypic plasticity axes define distinct obesity sub-types’, published in the journal Nature Metabolism, offer a more nuanced understanding of obesity than current definitions and may one day inform more precise ways to diagnose and treat obesity and associated metabolic disorders. The study also reveals new details about the role of epigenetics and chance in health and provides insights into the link between insulin and obesity.
Bariatric and metabolic surgery will be covered by health insurance in Saudi Arabia from 1 October in a move to improve the nation’s health by treating and reducing obesity rates in the Kingdom, according to a report in Okaz/Saudi Gazette.
Researchers from the Mayo Clinic, Rochester, MN and the Mayo Clinic, Jacksonville, FL, have reported findings from a cohort study that suggest semaglutide is clinically effective for weight loss at three and six months for people with overweight or obesity. Interestingly, although their study lacked the stringent and closely controlled nature of randomised clinical trials (RCTs), they found similar weight loss results within the same time period as in RCTs.